Cannabis and Cardiovascular Health: Peer-Reviewed Research Consensus

213 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis and your body includes 213 peer-reviewed studies spanning 1975–2026. Of these, 21 provide strong evidence, including 7 meta-analyses and 7 randomized controlled trials. Key findings with strong support include: largest-ever meta-analysis (183m patients) found cannabis use significantly associated with stroke risk but not heart attack risk — though observational data can't prove causation, and meta-analysis of 81 million participants found cannabis use associated with 71% higher atrial arrhythmia risk, with concurrent drug use and legal country status further increasing risk. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

Largest-ever meta-analysis (183M patients) found cannabis use significantly associated with stroke risk but not heart attack risk — though observational data can't prove causation

Strong Evidence
4 studies|All included studies were observational — the association between cannabis and stroke cannot be confirmed as causal. Residual confounding is a major concern: cannabis users may differ from non-users i

Meta-analysis of 81 million participants found cannabis use associated with 71% higher atrial arrhythmia risk, with concurrent drug use and legal country status further increasing risk

Strong Evidence
4 studies|All observational studies; heterogeneity in cannabis use definitions; cannot determine dose-response; confounding by tobacco and other substances; no teenage population data.

Meta-analysis of 100+ million participants plus genetic analysis confirms cannabis use disorder is causally linked to stroke, particularly large artery stroke

Strong Evidence
4 studies|Observational meta-analysis showed heterogeneity and small-study effects for cannabis. Mendelian randomization assumes certain conditions (no pleiotropy, relevant instruments) that may not be perfectl

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

A 1978 medical review identified cannabis as promising for glaucoma and asthma but flagged cardiovascular risks during exercise and preliminary concerns about lung and immune effects

Moderate Evidence
34 studies|As a narrative review from 1978, it reflects limited evidence available at that time. The cannabis landscape has changed dramatically in terms of product potency, consumption methods, and the volume o

A major 1986 pharmacological review found cannabis's greatest health concern was its impact on youth development, while finding no proven brain damage and limited physical dependence in adults

Moderate Evidence
34 studies|Reflects evidence available through the mid-1980s. Cannabis potency, usage patterns, and the volume of research have all changed dramatically. The review's reassurance about lung effects preceded mode

Review finding cannabis increases heart rate with rapid tolerance development, poses minimal risk for young healthy users but significant risks for people with existing cardiovascular disease

Moderate Evidence
34 studies|As a narrative review, the evidence was synthesized without systematic methodology. Most data came from studies in young, healthy subjects and may not apply to older or medically compromised populatio

Review comparing cardiovascular effects of five substance classes, finding cannabis posed fewer heart risks than opiates, amphetamines, or alcohol, though cognitive effects were noted

Moderate Evidence
34 studies|The review covered five substance classes in a single paper, limiting depth on each. The cardiovascular effects of cannabis were not extensively detailed in the abstract. The cognitive effects mention

What We Still Don't Know

  • Only 7 randomized controlled trials exist out of 213 studies — most evidence is observational or from reviews.
  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Meta-Analyses & Systematic Reviews(Tier 1)
7 (3%)
Randomized Controlled Trials(Tier 2)
7 (3%)
Observational & Cohort(Tier 3-4)
36 (17%)
Reviews & Scoping(Tier 4)
54 (25%)
Case Reports & Animal(Tier 5)
43 (20%)
Other
66 (31%)

Key Studies

The most impactful research in this area.

Cannabis, Cocaine, and Amphetamines All Linked to Higher Stroke Risk in Major Analysis

The Mendelian randomization component is crucial because it uses genetic variation to approximate a natural experiment, providing stronger evidence for causation than observational studies alone. Finding that cannabis use disorder is genetically linked to large artery stroke is a significant public

2026

Cannabis use was associated with a 71% increased risk of atrial arrhythmias

As cannabis use expands globally, the cardiovascular risk profile is becoming clearer, and atrial arrhythmias represent a serious but potentially underrecognized consequence.

2025

Cannabis and Heart Attack/Stroke Risk: A 183-Million-Patient Meta-Analysis Finds Stroke Risk but Not Heart Attack Risk

This is the largest meta-analysis of cannabis and cardiovascular risk ever conducted. With over 183 million patients, it has statistical power that individual studies lack. The finding that stroke risk is elevated while heart attack risk is not suggests cannabis may affect the cardiovascular system

2023

JAMA's Comprehensive Review of What Cannabis Can and Can't Treat

A JAMA review represents the medical establishment's current consensus position. The fact that it was published in 2026 — years after most US states legalized some form of cannabis — signals that the medical community is still working to align clinical practice with evidence. The review's distinctio

2026

Meta-Analysis Finds Cannabis Users Have Twice the Risk of Ischemic Stroke

Ischemic stroke among young adults is increasing globally, paralleling rising cannabis use. This meta-analysis provides the strongest pooled evidence to date that cannabis use approximately doubles stroke risk, a finding with particular relevance as legalization expands and cannabis is increasingly

2025

Cannabis Users Had 48% Higher Risk of Cardiovascular Events in Large Meta-Analysis

Whether cannabis causes cardiovascular disease has been debated for years. This meta-analysis of nearly 1.9 million people provides the strongest pooled estimate to date, showing a significant association with composite cardiovascular events even if individual endpoints fall short of significance.

2025

Research Timeline

How our understanding of this topic has evolved.

Pre-2000

6 studies published. Includes 2 RCTs.

2000–2009

9 studies published. Predominantly observational and review studies.

2010–2014

13 studies published. Predominantly observational and review studies.

2015–2019

43 studies published. Includes 1 RCTs, 1 strong-evidence studies.

2020–present

142 studies published. Includes 7 meta-analyses, 4 RCTs, 20 strong-evidence studies.

About This Consensus

This consensus synthesizes 213 peer-reviewed studies: 7 meta-analyses (3%), 7 randomized controlled trials (3%), 36 observational studies (17%), 54 reviews (25%), 43 case studies (20%), 66 other study types (31%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 213 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.